HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Annamaria Offidani Selected Research

Allantoin

1/2021Effects of in vivo application of an overnight patch containing Allium cepa, allantoin, and pentaglycan on hypertrophic scars and keloids: Clinical, videocapillaroscopic, and ultrasonographic study.
1/2014Elastosis perforans serpiginosa: a case successfully treated with intralesional steroids and topical allium cepa-allantoin-pentaglycan gel.
9/2010Effect of allium cepa-allantoin-pentaglycan gel on skin hypertrophic scars: clinical and video-capillaroscopic results of an open-label, controlled, nonrandomized clinical trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Annamaria Offidani Research Topics

Disease

35Psoriasis (Pustulosis Palmaris et Plantaris)
06/2022 - 01/2015
16Infections
12/2021 - 03/2013
12Hidradenitis Suppurativa
06/2022 - 03/2017
10Melanoma (Melanoma, Malignant)
04/2022 - 11/2002
10Neoplasms (Cancer)
04/2022 - 11/2002
10Skin Diseases (Skin Disease)
12/2021 - 02/2018
9Hyperhidrosis
07/2022 - 01/2003
9Wounds and Injuries (Trauma)
11/2021 - 01/2008
8COVID-19
04/2022 - 11/2020
6Atopic Dermatitis (Atopic Eczema)
02/2022 - 01/2021
6Wound Infection (Wound Infections)
10/2021 - 01/2008
4Actinic Keratosis
11/2021 - 01/2016
4Skin Neoplasms (Skin Cancer)
11/2021 - 12/2019
4Hypersensitivity (Allergy)
09/2021 - 03/2021
4Sepsis (Septicemia)
09/2019 - 01/2016
3Neoplasm Metastasis (Metastasis)
04/2022 - 04/2015
3Chronic Urticaria
04/2021 - 01/2021
3Cicatrix (Scar)
03/2021 - 01/2017
3Cutaneous Malignant Melanoma
10/2020 - 06/2015
3Surgical Wound
12/2019 - 04/2008
3Nevus (Nevi)
01/2018 - 11/2002
3Burns
01/2017 - 01/2012
3Necrosis
09/2016 - 11/2014
3Staphylococcal Infections
01/2016 - 06/2008
2Eczema
02/2022 - 07/2021
2Psoriatic Arthritis
11/2021 - 01/2018
2Squamous Cell Carcinoma of Head and Neck
10/2021 - 06/2021
2Mycosis Fungoides
07/2021 - 01/2016
2Hypertrophic Cicatrix (Hypertrophic Scar)
01/2021 - 09/2010
2Keloid
01/2021 - 09/2010
2Urticaria (Hives)
01/2021 - 01/2021
2Ulcerative Colitis
09/2020 - 01/2018
2Oral Lichen Planus
02/2020 - 12/2015
2Pyoderma Gangrenosum
05/2019 - 01/2019
2Crohn Disease (Crohn's Disease)
01/2018 - 03/2017
2Inflammation (Inflammations)
12/2015 - 03/2015
2Pigmented Nevus (Melanocytic Nevus)
06/2015 - 11/2002
1Abscess
06/2022

Drug/Important Bio-Agent (IBA)

14Biological ProductsIBA
02/2022 - 02/2018
11Adalimumab (Humira)FDA Link
06/2022 - 03/2016
10Biomarkers (Surrogate Marker)IBA
09/2021 - 06/2015
7secukinumabIBA
04/2022 - 01/2017
7Anti-Bacterial Agents (Antibiotics)IBA
01/2022 - 06/2008
7Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
10/2021 - 11/2002
6Pharmaceutical PreparationsIBA
07/2022 - 03/2015
6Nicotinamide N-MethyltransferaseIBA
11/2021 - 01/2018
6EnzymesIBA
11/2021 - 01/2018
5Botulinum Toxins (Botulinum Toxin)IBA
07/2022 - 01/2003
5Infliximab (Remicade)FDA Link
02/2022 - 01/2016
5Etanercept (Enbrel)FDA Link
02/2022 - 09/2016
5Type A Botulinum Toxins (Botox)FDA Link
01/2022 - 01/2003
5Interleukin-17 (Interleukin 17)IBA
10/2021 - 06/2015
5CytokinesIBA
10/2021 - 01/2017
5Tigecycline (Tygacil)FDA Link
01/2018 - 01/2012
4dupilumabIBA
02/2022 - 06/2021
4N-nitroso-N-methyltyramine (NNMT)IBA
11/2021 - 01/2018
4Aryldialkylphosphatase (Paraoxonase)IBA
11/2021 - 01/2020
4Interleukin-23 (Interleukin 23)IBA
04/2021 - 06/2015
4Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
11/2019 - 07/2015
4TeicoplaninIBA
12/2016 - 01/2008
3Ustekinumab (CNTO 1275)FDA Link
02/2022 - 01/2017
3VaccinesIBA
12/2021 - 04/2021
3Monoclonal AntibodiesIBA
10/2021 - 01/2017
3ixekizumabIBA
09/2021 - 01/2017
3Omalizumab (Xolair)FDA Link
04/2021 - 01/2021
3AllantoinIBA
01/2021 - 09/2010
3SteroidsIBA
06/2020 - 01/2014
3InterleukinsIBA
01/2017 - 03/2016
3Matrix Metalloproteinase 9 (Gelatinase B)IBA
06/2013 - 11/2002
2Cholinergic Antagonists (Anticholinergics)IBA
01/2022 - 03/2015
24-amino-4'-hydroxylaminodiphenylsulfone (HADS)IBA
11/2021 - 01/2021
2apremilastIBA
11/2021 - 01/2021
2Dacarbazine (DIC)FDA LinkGeneric
11/2021 - 12/2020
2CollagenIBA
10/2021 - 06/2013
2Niacinamide (Nicotinamide)FDA LinkGeneric
09/2021 - 08/2020
2Immunosuppressive Agents (Immunosuppressants)IBA
08/2021 - 09/2019
2Messenger RNA (mRNA)IBA
04/2021 - 10/2020
2Interleukin-12 (IL 12)IBA
04/2021 - 01/2017
2dalbavancinIBA
01/2021 - 01/2020
2NeurotoxinsIBA
01/2021 - 03/2017
2calcipotriene (calcipotriol)FDA LinkGeneric
01/2021 - 06/2020
2oxybutynin (Tavor)FDA LinkGeneric
11/2020 - 03/2015
2Antirheumatic Agents (DMARD)IBA
04/2020 - 11/2019
2AntioxidantsIBA
01/2020 - 01/2019
2golimumabFDA Link
11/2019 - 01/2019
2pexigananIBA
01/2018 - 01/2016
2CopperIBA
01/2017 - 01/2012
2DaptomycinFDA Link
01/2017 - 12/2016
2Colistin (Coly-Mycin)FDA Link
12/2016 - 01/2016
2SurvivinIBA
12/2015 - 04/2015
1guselkumabIBA
06/2022
1TetraspaninsIBA
04/2022

Therapy/Procedure

31Therapeutics
07/2022 - 06/2008
10Biological Therapy
02/2022 - 01/2017
3Aftercare (After-Treatment)
11/2021 - 01/2003
3Phototherapy (Light Therapy)
01/2021 - 11/2010
2Immunomodulation
04/2022 - 11/2020
2Contraindications
07/2021 - 04/2021
2Immunotherapy
06/2020 - 01/2018
2Physical Therapy Modalities (Physical Therapy Technique)
01/2016 - 01/2003